CYTEK BIOSCIENCES INC (CTKB)
Health Care · Spectral flow cytometry and cell analysis instrumentation · NASDAQ
Cytek Biosciences sells spectral flow cytometry instruments and integrated cell analysis platforms powered by patented Full Spectrum Profiling technology that enable high-resolution, high-dimensional single-cell analysis for biomedical research and clinical applications.
What CYTEK BIOSCIENCES INC does
Cytek Biosciences is a leading cell analysis solutions company that develops and commercializes instruments, reagents, software, and services for single-cell analysis. The company's proprietary Full Spectrum Profiling (FSP) technology leverages the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells with high sensitivity and dimensional depth. The company sells its cell analyzers (Aurora, Northern Lights, Aurora Evo, Aurora CS sorter) and integrated platform solutions globally to pharmaceutical, biopharma, academic research, and contract research organization customers.
Themes: ["Flow cytometry / cell analysis","Single-cell analysis","High-dimensional cell profiling","Biomedical research tools","Immunology and oncology applications","Clinical diagnostics","Cell sorting and isolation"]
Fundamentals
- Price$4.59 as of 2026-07-09 close
- Market cap$593M as of 2026-07-10
- 1-year return+28.2% as of 2026-07-09 close
- Net margin-36.3% as of 2026-07-10
- Gross margin+51.7% as of 2026-07-10
- ROE-20.8% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)+3.6% as of 2026-07-10
- Revenue CAGR (3y)+7.1% SEC XBRL
- Beta1.18 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative 36.25% net margin and may require continued investment in R&D, commercial infrastructure, and sales expansion to achieve profitability.","Revenues are growing slowly (3.61% YoY) and net losses widened in Q1 2026 ($18.9M) versus prior year ($11.4M), indicating margin pressure and execution challenges.","Competition from established cell analysis technology providers using conventional flow cytometry, mass cytometry, and other spectral flow cytometry approaches that may have greater market penetration, installed base, or resources."]
Competitors & peers
- BD Biosciences (flow cytometry systems)
- Beckman Coulter (cell analyzers)
- Sony Biotechnology (spectral flow cytometry)
- Thermo Fisher Scientific (cell analysis)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.